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Abstract
Background: Her2/neu is overexpressed in various human cancers of epithelial origin and is
associated with increased metastatic potential and poor prognosis. Several attempts have been
made using the extracellular domain of Her2/neu (ECD/Her2) as a prophylactic vaccine in mice
with no success in tumor prevention.
Methods: The extracellular domain of Her2/neu (ECD/Her2) was expressed in yeast P. pastoris, in
a soluble highly mannosylated form. The immune response of the immunization with this
recombinant ECD/Her2 was analyzed using immunoprecipitation and western blot analysis,
proliferation and cytotoxicity assays as well as specific tumor growth assays.
Results: Mannosylated ECD/Her2 elicited a humoral response with HER2/neu specific antibodies
in vaccinated mice, which were able to reduce the proliferation rate of cancer cells in vitro.
Moreover, it elicited a cellular response with Her2/neu-specific CTL capable of lysing tumor cells,
in vitro. When immunized Balb/c and HHD mice were challenged with Her2/neu-overexpressing
cells, tumor growth was inhibited.
Conclusion: Here we report on the efficacy of the extracellular domain of human Her2/neu
produced in yeast P. pastoris, which confers mannosylation of the protein, to act as a potent anti-
tumor vaccine against Her2/neu overexpressing tumors. Specific cellular and humoral responses
were observed as well as efficacy.
Background
The Her2/neu (ErbB2) gene encodes a 185 kDa trans-
membrane glycoprotein that belongs to the family of epi-
dermal growth factor receptors. It consists of a 620 aa
extracellular domain, followed by a 23 aa transmembrane
domain and a 490 aa intracellular domain with a tyrosine
kinase activity [1]. It is a ligand-less receptor and it is the
preferred heterodimerization partner for ligand-bound
EGFR, Her3 and Her4, serving as a co-receptor. Any alter-
ation of the firmly regulated EGF receptor signaling path-
ways leads to cellular abnormalities and tumorigenesis
[2].
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The Her2/neu gene has a low expression in normal tis-
sues. However, it is amplified and overexpressed in ~30%
of invasive breast carcinomas and it is associated with
increased metastatic potential and poor prognosis. Over-
expression of the Her2/neu receptor is also observed in
various other human cancers, including lung, ovary, kid-
ney, and bladder [3]. Several reports have shown that the
Her2/neu molecule is immunogenic, since it may gener-
ate antibodies and peptide-specific CTL response in some
patients [4]. Therefore Her2/neu is an attractive target for
active immunotherapy. DNA- and peptide-based vaccines
were able to break tolerance and generate tumor antigen-
specific immunity in animal models [5-8]. However,
when the extracellular domain of the Her2/neu protein,
produced in cell lines which confer normal mammalian
glycosylation, was used as a vaccine, it could not confer
protection against Her2/neu overexpressing tumors [9-
11]. An effective immune response was elicited only when
ECD/Her2 was fused to cytokines [12] or combined with
antibodies fused to cytokines [11]. Given that antigen pre-
senting cells (APCs) do recognize and direct manno-
sylated antigens for degradation [13], it was recently
shown that the use of fungal systems to mannosylate vac-
cine candidates can enhance immunogenicity in the con-
text of CD4+ [14] and CD8+ T cells [15]. The present study
utilizes the mannosylated extracellular domain of the
human HER2/neu receptor (ECD/Her2) produced in yeast
P. pastoris to reduce tumor growth. ECD/Her2 elicited a
humoral response in vaccinated mice with specific anti-
bodies against Her2/neu that were able to reduce the pro-
liferation rate of cancer cells in vitro. It, also, elicited a
cellular response with Her2/neu-specific CTL capable of
lysing tumor cells in vitro. When Balb/c and HHD vacci-
nated mice were challenged with Her2/neu overexpress-
ing cells, tumor growth was inhibited. These results
suggest that ECD/Her2 is a good candidate for a tumor
antigen vaccine as it prolongs tumor free survival and
overall survival of vaccinated mice.
Methods
Animals
Female BALB/c obtained from Harlan Laboratories (Indi-
anapolis, IN, USA) and HHD mice (β2 m
-/-, H-2Db-/- and
expressing a HLA.A2.1 monochain composed of a chi-
meric heavy chain, α1 and α2 domains of HLA-A*0201
and the α3 intracellular domain of Db [16]) obtained
from Institut Pasteur (Paris, France), were used.
All mice were maintained in pathogen-free conditions in
the animal facilities of the Hellenic Pasteur Institute.
Experiments were performed according to the Greek and
European regulations on Animal Welfare and with Public
Health Service recommendations.
Cell lines
D2F2/E2, a mouse mammary tumor cell line stably trans-
fected with the human Her2/neu molecule, was previ-
ously described [17]. This cell line, as well as the parental
D2F2 cell line, was maintained in hi-glucose DMEM, sup-
plemented with 100 units/mL Penicillin, 100 μg/mL
Streptomycin, 10% FBS, 10% NCTC 109, 1% non-essen-
tial amino acids and 5% Sodium Bicarbonate.
ALC.A2.1.hHer2, a murine lymphoma cell line stably
transfected with the HLA.A2.1 and the human Her2/neu
molecule [8] and the SK-BR-3 cell line were maintained in
RPMI 1640, supplemented with 100 units/mL Penicillin,
100 μg/mL Streptomycin and 10% FBS.
All cell lines were maintained at 37°C under a 5% CO2 -
95% air atmosphere.
Soluble expression of ECD/Her2 in yeast Pichia pastoris
The extracellular domain of human Her2/neu receptor
(ECD/Her2, aminoacid residues 1 - 627) was previously
enzymatically amplified by PCR and subcloned into the
expression vector pPICZaC (Invitrogen, Carlsbad, Califor-
nia, USA) for soluble expression in yeast P. pastoris [18].
Protein production was induced with methanol while
cells were grown at 30°C for 72 h. The culture supernatant
was passed through a 0.22 - μm membrane filter, concen-
trated using the Minitan Ultrafiltration System (Millipore,
Billerica, Massachusetts, USA) equipped with 30 kDa cut-
off membrane and then dialyzed extensively against 20
mM sodium phosphate buffer pH 7.4, containing 0.5 M
NaCl and 10 mM Imidazole. The concentrated protein
was purified over a Ni2+ affinity chromatography using
HisTrap FF column and a FPLC AKTA Purifier system
(Amersham Biosciences, Munich, Germany) under native
conditions, according to the manufacturer's protocol. The
recombinant protein was filtrated and stored at -80°C.
In order to deglycosylate the produced molecule, approx-
imately 3 μg of ECD/Her2 were denatured at 100°C for 10
min in a buffer containing 0.5% SDS and 1% β-mercap-
toethanol. 50 mM sodium phosphate and natural phos-
phate (NP) to a final concentration of 1% were added,
and the protein was incubated with 500 U N-glycosidase
F (PNGase F, New England Biolabs, Ipswich, Massachu-
setts, USA) for 1 h at 37°C, in a total reaction volume of
80 μl.
Immunization protocol
Mice at the age of 6-8 weeks were immunized (day 0) by
subcutaneous (s.c.) injection at the base of the tail with
either PBS (control group) or 25 μg ECD/Her2 emulsified
in complete Freund's adjuvant (CFA) (SIGMA, St. Louis,
Missouri, USA). Two boosts of the same dose emulsified
in incomplete Freund's adjuvant (IFA) (SIGMA) were car-BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
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ried out 21 and 42 days later. Mice weight was measured
as an indicator of toxicity caused by vaccinations. Blood
samples were taken by tail bleeding before each vaccina-
tion, as well as 10, 21 and 42 days after the last vaccina-
tion.
Tumor model
10 days after the last immunization mice were challenged
by s.c. injection into the left flank of 1 × 105 D2F2/E2 or
D2F2 tumor cells (BALB/c mice), or 3 × 105
ALC.A2.1.hHer2 tumor cells (HHD mice). Tumor cells
were suspended in sterile PBS. Animals were monitored
twice per week for the development of palpable tumors.
Tumors were measured by calliper and the tumor volume
was calculated using the formula tumor volume = (length
× width2)/2. Mice were sacrificed with euthanasia when
the tumor volume grew up to 2000 mm3.
ELISA assay
Sera from immunized mice were analyzed for anti-ECD/
Her2 reactivity in enzyme-linked immunosorbent assays
(ELISA). Ninety-six-well microtiter plates were coated
with 20 μg/mL ECD/Her2 for 16 hrs at 4°C. Non-specific
binding sites were blocked with PBS/3% BSA for 1 h at
37°C. Plates were incubated with sera dilutions in PBS/
1% BSA, in triplicates, overnight at 4°C. Anti-ECD/Her2
antibodies were detected using goat anti-mouse IgG con-
jugated to horseradish peroxidase (DAKO Cytomation,
Glostrup, Denmark) in PBS/1% BSA, for 1 h at 37°C.
Reactions were developed after the addition of TMB sub-
strate, and then stopped with the addition of 50 μL/well 1
M sulfuric acid. Absorbance was read on a microtiter plate
reader (BioRad, Hercules, California, USA).
Immunoprecipitation and Western blot analysis
Pooled sera from groups of immunized mice were used to
immunoprecipitate human Her2/neu from SK-BR-3 cell
membrane lysates. 1 μg Herceptin (Trastuzumab) was
used as a positive control, and PBS as negative control.
200  μL beads Gammabind Sepharose (Amersham,
Munich, Germany) were pre-incubated with SK-BR-3 cell
membrane lysate for 2 hours at room temperature, in
order to avoid any non-specific binding. 2 μL of sera were
incubated with 600 μg of cell membrane lysate overnight
at 4°C. 30 μL of Gammabind Sepharose were added and
the solution was gently rocked for 2 h at room tempera-
ture. Sepharose pellets were washed twice with TSA solu-
tion (0.01 M Tris-HCl pH 8, 0.14 M NaCl, 0.025% NaN3)
containing 0.1% Triton-X and once with TSA alone.
Immunoprecipitates were separated on 8% SDS-PAGE
gels and blotted onto PROTRAN nitrocellulose mem-
branes (WHATMAN, Dassel, Germany). The membranes
were blocked with 5% non-fat milk in PBS, 0.1% Tween-
20. Her2/neu was detected by immunoblotting with C-18
rabbit anti-Her2/neu (Santa Cruz Biotechnology, Santa
Cruz, California, USA), overnight at 4°C. Goat anti-rabbit
IgG conjugated to horseradish peroxidase (DAKO Cyto-
mation, Glostrup, Denmark) was the secondary antibody
and bound antibodies were visualized by chemilumines-
cence using the ECL-Western Blot detection system
(Amersham, Munich, Germany). Membranes were
exposed to X-ray film (Amersham, Munich, Germany).
SK-BR-3 in vitro proliferation assay
Single cell suspensions of 5 × 103 SK-BR-3 cells were left to
adhere overnight at 96-well culture plates at 100 μL/well
of RPMI-1640 containing 5% FBS. Pooled sera from each
group of vaccinated mice were depleted of complement
by incubation at 56°C for 30 minutes, diluted in serum-
free culture medium to give a final working dilution of
1:100 and added to SK-BR-3 cells, which were then incu-
bated for 3 days at 37°C. The number of living cells was
determined by CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega, Madison, Wisconsin, USA).
Cytotoxicity assay
ECD/Her2 or PBS immunized mice were used 10 days
after the last vaccination, to isolate CD8+ T cells from total
immune splenocytes by negative selection using the
CD8a+ T Cell Isolation Kit (Miltenyi Biotec, Bergisch Glad-
bach, Germany). Freshly isolated CD8+ T cells were used
for cytotoxicity assays using the CytoTox 96 Non-Radioac-
tive Cytotoxicity Assay (Promega, Madison, Wisconsin,
USA). Briefly, 5000 D2F2 or D2F2/E2 cells were coated in
each well of a 96-well v-bottom culture plate as target
cells. As effector cells, CD8+ T cells from immunized mice
were used at the indicated E:T ratios. Cytotoxicity is meas-
ured upon the lactate dehydrogenase (LDH) released
upon cell lysis. The percentage of cytotoxicity is calculated
according to the formula % cytotoxicity = 100 × (experi-
mental value - effector spontaneous LDH release - target
spontaneous LDH release)/(target maximum LDH release
- target spontaneous LDH release). Cytotoxicity values
were considered to indicate significant lytic activity of a
target when the differences between mean values for %
lysis of target cells from ECD/Her2 vaccinated mice and
PBS vaccinated mice were >10% and statistically signifi-
cant (p < 0.05).
Statistical analysis
The statistical significance of differential findings between
experimental groups was determined by student's t test.
Findings were regarded as significant, if p values were <
0.05. Tumor sizes among the groups were compared with
Mann-Whitney U test using the SPSS (v.16.0) program.
Kaplan-Meier curves were plotted for tumor free analysis.
All p values were two tailed and considered significant
when p < 0.05.BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
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Results
Soluble expression of ECD/Her2 in yeast P. pastoris
The recombinant human ECD/Her2 expressed in soluble
form in yeast P. pastoris, was purified using Ni2+ affinity
chromatography. The molecular size of the product was
estimated as ~120-210 kDa higher than that predicted
from the amino acid sequence (73 kDa). This difference
was shown to be due to glycosylation of the molecule
since enzymatic deglycosylation using peptide N-glycosi-
dase F resulted in a reduction in the apparent molecular
size to about 85 kDa (figure 1). These results show that the
ECD/Her2 is highly mannosylated, as in P.pastoris the N-
linked and O-linked glucans are terminally manno-
sylated. The yield of the isolated protein was approxi-
mately 0.4 mg/l.
Vaccination with the mannosylated ECD/Her2 expressed 
in P. pastoris elicits a humoral response against Her2/neu
To determine whether the recombinant mannosylated
ECD/Her2 expressed in yeast P. pastoris could induce a
humoral immune response, groups of BALB/c mice were
immunized with the recombinant protein or PBS emulsi-
fied in CFA s.c., followed by two boosts in IFA on days 21
and 42. Immunized mice with the recombinant human
ECD/Her2 developed specific antibodies against ECD/
Her2 as measured by ELISA (figure 2). The levels of anti-
ECD/Her2 antibodies detected after the first immuniza-
tion (day 21) were increased by two times after the first
boost (day 42) reaching a plateau. The antibody titer
remained high (above 1:105) even 40 days after the last
vaccination (day 82). Anti-ECD/Her2 antibodies were not
present in control mice which were injected with PBS,
while the increased background level 30 days after the
tumor challenge (day 82-see below) is due to the Her2/
neu molecule that is expressed in the surface of D2F2/E2
transfected cell lines. Mice weight was measured as an
indicator of toxicity caused by vaccinations and no differ-
ences were obtained compared to PBS vaccinated mice
(data not shown).
In order to investigate whether these antibodies produced
in ECD/Her2- immunised mice were able to react with the
native human Her2/neu, we performed immunoprecipi-
tation assay. As shown in figure 3, the antibodies pro-
duced in ECD/Her2-immunized mice were specific
against the native Her2/neu receptor of SK-BR-3 cells.
These antibodies were not present in sera from PBS-
immunised mice.
In vivo antitumor activity of the mannosylated ECD/Her2 
in BALB/c mice
The in vivo antitumor activity of the recombinant manno-
sylated ECD/Her2 was tested in BALB/c mice. Groups of 9
mice were injected s.c. with the recombinant ECD/Her2 or
PBS on day 0, followed by two boosts on days 21 and 42.
10 days after the last boost (day 52), 1 × 105 human Her2/
neu expressing syngeneic murine cells D2F2/E2 or wild-
type D2F2 were injected s.c. into the left flank of vacci-
nated mice. Tumors grew progressively in all PBS and
ECD/Her2 immunised mice injected with D2F2 cells
(data not shown). However, as shown in figure 4A, ECD/
Her2 immunization significantly prolonged tumor free
survival in D2F2/E2 injected mice (day 58) compared to
PBS immunized mice (day 31), (p < 0.01). 2 mice became
long-term survivors while the rest survived up to day 72
versus day 52 in the PBS-immunised mice (p < 0.01) (fig-
ure 4B). These data suggested that the vaccination of
BALB/c mice with the mannosylated ECD/Her2 delayed
the onset of tumor growth and in 2 mice provided full
protection.
Immune sera inhibits the growth of SK-BR-3 in vitro
We next exploited the anti-proliferative effect of antibod-
ies produced in ECD/Her2-immunized mice on the breast
cancer cell line SK-BR-3 which overexpress Her2/neu.
Diluted 1:100 pooled sera from vaccinated mice were
added to the cells and cell proliferation was determined
by MTS assay. Figure 5 shows that the diluted sera from
ECD/Her2-immunized mice were able to reduce the pro-
Deglycosylation of ECD by peptide N-glycosidase F (PNGase  F) Figure 1
Deglycosylation of ECD by peptide N-glycosidase F 
(PNGase F). Purified ECD incubated for 1 h at 37°C with 
(+) or without (-) PNGase F was analyzed in 8% SDS-PAGE. 
HMW, LMW: high and low molecular weight markers.BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
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liferation rate of SK-BR-3 by 13% (p < 0.05). In contrast,
no cell growth arrest was noted with sera from PBS-vacci-
nated mice, whereas Herceptin that was used as positive
control antibody showed a strong inhibition effect (35%)
at 6 nM. These data show that the antibodies contained in
sera from ECD/Her2-immunized mice have significant
anti-proliferative effects in SK-BR-3 cells.
CD8+ T cells from immunized mice are able to lyse tumor 
target cells
Having demonstrated that ECD/Her2 vaccination elicits
antibodies capable of reducing the proliferation rate of
Her2-overexpressing tumor cells, we then sought to eval-
uate Her2/neu-specific CTL responses induced in the
same mice. Splenocytes were prepared 10 days after the
last immunization, and CD8+ T cells were isolated using
CD8a+ T Cell Isolation Kit. As shown in figure 6, CD8+ T
cells isolated from PBS-immunized mice showed basal
lytic activity against D2F2/E2 cells, while CD8+ T cells iso-
lated from ECD/Her2-immunized mice exhibited signifi-
cantly increased lytic activity (p < 0.01). Negligible levels
of cytotoxicity against wild type D2F2 cells were observed
with CD8+ T cells isolated from ECD/Her2- or PBS-immu-
nized mice (data not shown).
In vivo antitumor activity of the recombinant ECD/Her2 in 
HHD mice
The in vivo antitumor activity of the recombinant ECD/
Her2 was also evaluated in a second animal model.
Groups of HHD mice were injected s.c. with ECD/Her2 (n
= 4) or PBS (n = 4) on day 0, followed by two boosts on
days 21 and 42. Specific antibodies against the ECD/Her2
and the native Her2/neu were developed in ECD/Her2
vaccinated mice that were able to reduce the proliferation
rate of SK-BR-3 cells (data not shown). 10 days after the
last boost (day 52) mice were challenged s.c. into the left
flank with 3 × 105 ALC tumor cells stably transfected with
Her2/neu and HLA.A2.1 (ALC.A2.1.hHer2). Tumors grew
progressively in all PBS immunized mice. Impressively,
however, ECD/Her2 immunization fully protected 3 out
of 4 (75%) mice against tumor growth (figure 7).
Discussion
In the present study we showed that immunization with
the mannosylated extracellular domain of the human
Her2/neu receptor produced in yeast P. pastoris can induce
anti-Her2/neu antibodies capable of reducing the prolifer-
ation rate of SK-BR-3 cells in vitro. In addition, manno-
sylated ECD/Her2 vaccination elicits specific CTL
responses against Her2/neu overexpressing tumor cells.
Both humoral and cellular responses delay and in some
Vaccination with the mannosylated ECD/Her2 expressed in P. pastoris elicits a humoral response Figure 2
Vaccination with the mannosylated ECD/Her2 expressed in P. pastoris elicits a humoral response. Anti-ECD/
Her2 antibodies in the sera of mice immunized with ECD/Her2 or PBS, as measured with enzyme-linked immunosorbent assay 
(ELISA). Sera were collected at various times. Pooled sera from the two groups of mice were assayed at a 1:1000 dilution. Col-
umns and error bars represent the means and the range of values obtained from 3 independent experiments. ECD mice: ECD/
Her2 vaccinated mice. PBS mice: PBS vaccinated mice (control group).BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
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cases even prevent the formation of tumors in challenged
mice.
The era of anti-Her2/neu vaccine development began
when it was shown that a certain percentage of breast can-
cer patients with Her2/neu+ tumors had pre-existent T-
and B-cell mediated immunity to the Her2/neu protein
[4]. Since then several attempts were made towards this
direction. Several studies reported that mice immunized
with DNA encoding full length or truncated forms of
Her2/neu developed resistance against Her2/neu - overex-
pressing tumors, via mechanisms involving antibodies
and CD8+ T cells [5,10,19]. Peptides derived mostly from
cryptic sequences of the extracellular or the intracellular
domain of Her2/neu, have also been used as vaccines
leading to the generation of CTL-specific responses with
potent antitumor immunity [6-8]. Whole fragments of
Her2/neu have, finally, been used as candidate vaccines
against Her2/neu overexpressing tumors. The intracellular
domain of Her2/neu produced in E. coli has been shown
to partially inhibit the growth of cancer cells [10]. How-
ever the extracallular fragment produced in various trans-
fected cell lines such as DHFR/G8, BHK/erbB2 and L cells
which confer normal mammalian glycosylation and not
mannosylation, could not confer any protection against
growing tumors [9,11]. In contrast, when the ECD/Her2
was fused to cytokines like GM-CSF [12], or combined
with anti-Her2/neu IgG3 antibodies fused to cytokines IL-
2, IL-12 and GM-SCF [11], both humoral and cell-medi-
ated responses against Her2/neu were observed.
The soluble expression of human ECD/Her2 molecule in
yeast P. pastoris produced a highly mannosylated recom-
binant protein. Mannosylated antigens are recognized by
mannose receptors (MRs), found on macrophages and
dendritic cells. These receptors have the capacity to direct
internalized antigens into endocytic and phagocytic path-
ways [13]. As a result, antigens are presented in major his-
tocompatibility complexes class I and II and subsequently
CD4+ T cells [14] and CD8+ T cells are activated [15].
According to this, the aim of our study was to evaluate
whether the mannosylation of the ECD/Her2 produced in
P. pastoris can potentiate the anti-tumor response of vacci-
nated mice. By using two tumor/mouse models we could
show that vaccination with the mannosylated ECD/Her2
could induce effective antitumor activity in vivo. In partic-
ular, the growth of D2F2/E2 (transfected to express
human HER-2/neu), but not of wild-type D2F2 cells, was
significantly slowed down in 7 of 9 vaccinated BALB/c
animals whereas the remainders became long-term survi-
vors. In the second model, we utilized the HHD mouse
model as a platform for active antitumor immunization.
The relevance of the HHD model at identifying actual
HLA.A2.1-restricted peptides has been demonstrated by
the ability of these peptides to stimulate in vitro human
PBMC derived from both healthy and cancer donors [20-
22]. There is evidence for the overall correlation between
the HLA.A2.1-binding capacity of the peptides and their
immunogenicity in HHD mice [23]. We and others have
previously shown that HHD-derived T cells can lyse not
only peptide-pulsed targets but also tumor cells, which
express the corresponding epitope on their surface as a
result of endogenous tumor-associated antigen processing
[8,20-24]. HLA.A2.1 transgenic HHD mice rejected (3 of
4) the transplantable ALC tumors stable transfected to
express HLA.A2.1 and human Her2/neu. Thus, the in vivo
efficacy of the mannosylated ECD/Her2 in the models
used herein suggests that in addition to the antibody rec-
ognized epitopes, HLA.A2.1-restricted epitopes exist on
this domain which are immunogenic enough to induce
efficient antitumor CTL responses in vivo. Although, this
has not been formally proven herein, the data from the in
vivo induction of CTL in BALB/c animals lysing in vitro
D2E2/F2 targets, suggest that this is likely to be the case.
Specificity of antibodies against native Her2/neu Figure 3
Specificity of antibodies against native Her2/neu. 
Antibodies from sera of ECD/Her2-immunised mice are spe-
cific against the human Her2/neu molecule, as seen with 
immunoprecipitation assay. Her2/neu protein extracted from 
SKBR- cells immunoprecipitated with antibodies from immu-
nized sera and then subjected to immunoblotting using C18 
anti-Her2/neu antibody. Sera ECD mice: Sera from ECD/
Her2 vaccinated mice. Sera PBS mice: Sera from PBS vacci-
nated mice (control group). Positive control: Herceptin. 
Negative control: PBS. SK-BR-3 lysate: SK-BR-3 cell lysate 
was used for detection of Her2/neu molecular weight.BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
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Immunization with ECD/Her2 induces strong antitumor immunity in mice Figure 4
Immunization with ECD/Her2 induces strong antitumor immunity in mice. Groups of 9 mice were injected as 
described in Materials and Methods either with ECD/Her2 or with PBS on days 0, 21, and 42. 10 days after the last injection, 
mice were inoculated s.c. with 105 D2F2/E2 cells. This is one representative experiment of 3 performed. A. Kaplan-Meier 
curve was plotted for tumor free analysis. Unbroken line represents ECD/Her2 vaccinated mice and broken line PBS vacci-
nated mice (control group). B. Tumor growth in groups of vaccinated mice. The volume of individual tumors was calculated as 
(length × width2)/2. Curves represent individual mice. Black square represents ECD/Her2 vaccinated mice and open circle PBS 
vaccinated mice (control group). p < 0.01.
Influence of immunized sera on the in vitro proliferation of  SK-BR-3 cells Figure 5
Influence of immunized sera on the in vitro prolifera-
tion of SK-BR-3 cells. Diluted sera from ECD/Her2-immu-
nized mice were able to reduce the proliferation rate by 13% 
(p < 0.05). SK-BR-3 cells were incubated with complement 
inactivated pooled immune sera obtained from vaccinated 
mice one day prior to cell inoculation. Immune sera were 
diluted 1:100. Columns and error bars represent the means 
and the range of values obtained from 3 independent experi-
ments. Positive control: Herceptin.
CD8+ T cells from immunized mice are able to lyse tumor  target cells Figure 6
CD8+ T cells from immunized mice are able to lyse 
tumor target cells. In vitro CTL activity of CD8 T lym-
phocytes isolated from spleens of BALB/c mice immunized 
with ECD/Her2 (black square) or PBS (open circle). CD8 T 
cells from these mice were used as CTL effectors against 
D2F2/E2 targets at the indicated E/T ratios and exhibited sig-
nificantly increased lytic activity (p < 0,01). Points and error 
bars represent the means and the range of values obtained 
from 3 independent experiments.BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
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Negative selection in the thymus is capable of deleting
almost all of self-reactive T cells [25,26]. However,
because this process is not complete, several peripheral
tolerance mechanisms persist [26]. Because most known
tumor antigens, including Her2/neu, come from self-pro-
tein, these incompletely removed self-reactive T cells must
be activated before being applied to tumor immuno-
therapy. Recently, several reports have shown that xeno-
genic vaccination could break self-tolerance and inhibit
the progression of established tumor in syngeneic or
transgenic mouse models [27-29]. In our study, xenogenic
immunization with recombinant human ECD/Her2
induced robust antitumor responses against murine
tumor cell lines overexpressing human Her2/neu. Given
the high homology between human and murine Her2/
neu [30], we propose that our human ECD/Her2 vaccine
will also induce cross-reactive CTL against murine Her2/
neu, rejecting transplantable tumors expressing murine
Her2/neu, thus breaking tolerance against self-Her2/neu,
as also proposed in other tumor models based on xeno-
vaccinations [8,31]. In addition, given that ECD/Her2 is a
potential source of immunogenic determinants recog-
nized by CD4+ T helper cells [32], then it is obvious that
activation of the latter cell population will also lead to
generation of B cell clones producing anti-Her2/neu anti-
bodies, thus overcoming any tolerance mechanisms
affecting the B cell compartment.
The data from the injections in BALB/c mice also suggest
that in addition to the HLA.A2.1, H-2Kd and Dd-restricted
CTL epitopes on ECD/Her2 should exist. Whether these
are the same with the HLA.A2.1-restricted ones binding
with different affinities to the mouse class I alleles, or rep-
resent distinct ones, remains to be determined. Thus, the
identification of the immunogenic epitopes on ECD/Her2
represents the major aim of our future studies. Once these
have been identified, work will be needed to examine
their immunogenicity in the human system.
Conclusion
Taken altogether, our results show that mannosylation of
ECD/Her2 increases its capacity to act as an immunogenic
molecule in vivo, being effective as a vaccine. This may
have a broader applicability as a general concept for
increasing the potency of long-peptide or protein vac-
cines.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AM, AD and CNB designed the study. AD did the experi-
ments and drafted the manuscript. CG was involved in
cell cultures and purification of ECD/Her2. All authors
approved the final version of the manuscript.
Acknowledgements
This work was supported by grants from the PENED program of the GSRT 
(contract No. 03ED113).
We thank Dr Francois Lemonnier (Unite d'Immunite Cellulaire Antivirale, 
Institut Pasteur, Paris, France) for kindly providing the HHD mouse strain 
and Dr. S. Avrameas for valuable suggestions.
Protective effect induced by immunization with ECD/Her2 in HHD mice Figure 7
Protective effect induced by immunization with ECD/Her2 in HHD mice. A. Kaplan-Meier curve was plotted for 
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